Fw: HIVandHepatitis.com Newsletter, April 14, 2012

[Guest guest]

From: "HIVandHepatitis.com" <editor@...>Date: Sat, 14 Apr 2012 18:01:52 -0400 (EDT)<nelsonvergel@...>Reply editor@...Subject: HIVandHepatitis.com Newsletter, April 14, 2012Having trouble viewing this email?Click hereNewsletter for Saturday, April 14, 2012CROI: The Long and Winding Road to a Cure for HIVAt this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) there were significant signs that AIDS cure research is on its way up a long and winding road at the foot of a very big hill. CROI: HIV+ People with CD4 Counts Above 500 Match Life Expectancy of General PopulationPeople with HIV who respond well to antiretroviral therapy and achieve undetectable viral load and a CD4 T-cell count above 500 cells/mm3 can have a mortality rate similar to that of HIV negative people, but this is not the case for those with 350-500 cells/mm3. WHO Recommends Continued Antiretroviral Treatment for HIV+ Women after DeliveryThe World Health Organization this month published new guidance recommending that women with HIV who receive combination antiretroviral therapy during pregnancy for prevention of mother-to-child transmission should remain on ART on an ongoing basis, regardless of CD4 T-cell count. New VA and TAG Fact Sheets on Boceprevir and Telaprevir for Hepatitis CThe U.S. Department of Veterans Affairs and the Treatment Action Group have produced new fact sheets with information about the new hepatitis C virus (HCV) protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek). Forward this emailThis email was sent to nelsonvergel@... by editor@... | Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy.HIVandHepatitis.com | 584 Castro Street #272 | San Francisco | CA | 94114